NanoViricides, Inc. (NYSE American: NNVC) announced the filing of its quarterly report for the period ended March 31, 2026, detailing continued advancement of its broad-spectrum antiviral candidate NV-387 toward Phase II clinical development for MPox in the Democratic Republic of Congo, where regulatory approval for the trial has already been obtained. The company also outlined progress in its orphan-first regulatory strategy, including FDA orphan drug designation for measles granted subsequent to the quarter and additional applications targeting MPox and smallpox. This development underscores the potential of NV-387 as a versatile therapeutic platform capable of addressing multiple viral diseases with significant unmet medical needs.
NV-387 is the company’s lead drug candidate and is designed as a broad-spectrum antiviral agent. NanoViricides plans to develop it for the treatment of respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPox, smallpox, and measles. The company’s approach leverages its proprietary nanoviricide technology, which involves creating special purpose nanomaterials that target viruses directly. The recent regulatory milestones, including the approval for Phase II trials in the DRC and the orphan drug designation for measles, are critical steps in validating this technology and moving toward clinical use.
The orphan drug designation from the U.S. Food and Drug Administration (FDA) provides incentives for developing treatments for rare diseases, including seven years of market exclusivity upon approval, tax credits for clinical trial costs, and waiver of certain application fees. For measles, which remains a significant global health threat despite the availability of vaccines, this designation could accelerate development and provide a much-needed therapeutic option. Similarly, the company’s applications for MPox and smallpox orphan designations aim to address outbreaks and bioterrorism concerns, respectively.
NanoViricides’ strategy focuses on an orphan-first approach, seeking regulatory benefits for specific indications while building a broader clinical data package for NV-387. This approach reduces development costs and timelines, potentially allowing the company to bring the drug to market faster for niche patient populations. The Phase II trial in the DRC for MPox will evaluate the safety and efficacy of NV-387 in patients infected with the virus, which has caused significant outbreaks in Africa and beyond. The company has already obtained regulatory approval from the DRC’s health authorities, enabling the trial to proceed.
Beyond MPox and measles, NanoViricides is also developing NV-387 for other viral diseases. The company’s pipeline includes NV-CoV-2, a nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir, and NV-CoV-2-R, which encapsulates remdesivir within polymeric micelles. The company believes that the remdesivir-containing candidate could be approvable given remdesivir’s existing FDA approval, provided safety is comparable. Additionally, NanoViricides is exploring treatments for oral and genital herpes, viral eye diseases, influenza, HIV, hepatitis C, rabies, dengue, and Ebola, among others. This broad scope positions the company as a key player in the antiviral space, with the potential to address multiple public health challenges.
The company’s technology is based on intellectual property and proprietary know-how licensed from TheraCour Pharma, Inc. NanoViricides holds exclusive, sub-licensable field licenses for several viral diseases, including HIV, hepatitis B and C, rabies, herpes simplex, influenza, dengue, and coronaviruses. The company also intends to obtain licenses for RSV, poxviruses, and enteroviruses pending successful research. As with any drug development, the path to commercialization is lengthy and requires substantial capital. There can be no assurance that NV-387 or any other candidate will demonstrate sufficient effectiveness and safety for human clinical development or eventual approval.
For more information, visit the company’s newsroom at https://ibn.fm/NNVC and the full press release at https://ibn.fm/osO0q.
